Viewing Study NCT05605223



Ignite Creation Date: 2024-05-06 @ 6:15 PM
Last Modification Date: 2024-10-26 @ 2:45 PM
Study NCT ID: NCT05605223
Status: COMPLETED
Last Update Posted: 2023-12-14
First Post: 2022-10-28

Brief Title: Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France
Sponsor: University Hospital Strasbourg France
Organization: University Hospital Strasbourg France

Study Overview

Official Title: Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France Between 2006 and 2018
Status: COMPLETED
Status Verified Date: 2023-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Encephalitis
Brief Summary: The number of acute encephalitides diagnosed each year is gradually increasing reaching approximately 5 to 10100000 per year more than 50 of etiologies currently remain unknown The majority of them are acute encephalitis of infectious origin but it is estimated that 20 of encephalitis in northern Europe is related to an autoimmune mechanism with the majority of encephalitis with anti-NMDA Ac discovered recently in 2007 The study of a large American encephalitis cohort showed a death rate of 3 to 7 in cases of autoimmune encephalitis Furthermore delay in the initiation of effective treatment tumor removal or immunotherapy beyond 4 weeks is associated with a poor prognosis at 1 year

It is therefore necessary to better understand the signs of autoimmune encephalitis in order to recognize the disease quickly and to start a treatment quickly in order to improve the management and the prognosis of these children
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None